Roche Tasmar Phase IIIb trial in early Parkinson's, first-time levodopa users under way.
Executive Summary
ROCHE TASMAR PHASE IIIb EARLY PARKINSON's DISEASE STUDY is under way to look at tolcapone's ability to delay the onset of fluctuation (uncontrollable muscle movements) in patients receiving levodopa for the first time. In the six-year Delayed Onset of Fluctuation study, early Parkinson's disease patients are receiving tolcapone plus levodopa or levodopa alone.